Developer docs
API playgroundTry for free, no card

Search company profiles

Candel Therapeutics

Full company profile

uuid000044t

Namestring
Candel Therapeutics
Legal namestring
Candel Therapeutics
Websiteurl
candeltx.com
Company typeenum
Public
Founded yearint
2018
Descriptiontext

Candel Therapeutics is a clinical-stage biopharmaceutical company developing off-the-shelf viral immunotherapies designed to treat solid tumors through localized intratumoral injection combined with systemic immune activation. The company's lead asset, aglatimagene besadenovec (CAN-2409), is an adenoviral replication-defective gene construct encoding the herpes simplex virus thymidine kinase gene, which is injected directly into the tumor and, in combination with FDA-approved oral prodrugs such as valacyclovir, triggers immunogenic cell death and CD8+ T cell-mediated anti-tumor immunity. Its second clinical-stage asset, linoserpaturev (CAN-3110), is a replication-competent HSV engineered for tumor-selective replication by placing the ICP34.5 gene under the Nestin promoter, enabling killing of high-grade glioma cells while sparing healthy brain tissue. Both candidates are supported by the enLIGHTEN™ Discovery Platform, an AI-assisted platform for designing new HSV-based gene constructs.

Candel's lead clinical program targets men with intermediate-to high-risk localized prostate cancer; a 745-patient Phase 3 trial under a Special Protocol Assessment met its primary endpoint with a 30% improvement in disease-free survival and an 80% pathological complete response rate, supporting a planned BLA submission in Q4 2026 and a potential U.S. commercial launch in 2027. The company has also reported positive Phase 2 data in non-small cell lung cancer (median OS 25.4 months in ICI-refractory patients), borderline resectable pancreatic cancer (median OS 31.4 months vs 12.5 months in control), and recurrent high-grade glioma, with the NSCLC program funded for Phase 3 development and the pancreatic program paused pending additional capital. Across indications the therapies have received FDA Fast Track, RMAT, and Orphan Drug designations.

The business model is presently pre-revenue. Candel is publicly listed on Nasdaq (ticker: CADL) following a 2021 IPO and operates with a lean headcount of 11-50 employees based in Needham, MA. The company has accumulated roughly $194.8M in cash and equivalents and has secured approximately $230M in additional capital during 2025-2026, including a $130M term loan facility with Trinity Capital, a $100M contingent royalty agreement with RTW Investments, and a $100M public offering, with the stated objective of funding Phase 3 development, launch readiness, and a U.S. commercial launch via an integrated commercialization partnership with EVERSANA. Future revenue, once approved, is expected to derive from product sales of aglatimagene in localized prostate cancer, subject to tiered single-digit royalties owed to RTW on U.S. net sales.

Short descriptiontext

Candel Therapeutics is a clinical-stage biopharmaceutical company developing off-the-shelf viral immunotherapies (adenoviral CAN-2409 and HSV-based CAN-3110) that convert solid tumors into immune-active tissue. It serves patients with prostate, lung, pancreatic, and brain cancers and is preparing a Q4 2026 BLA filing for a 2027 U.S. launch in localized prostate cancer.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
101–250
akta.pro rankint
HeadquartersNeedham, United States
HQ citystring
Needham
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
viral immunotherapy, cancer immunotherapy, oncolytic virus therapy, gene therapy oncology, solid tumor treatment
Industry1 code
PRIMARYHLAAACAF
Oncology Gene Therapies (incl. oncolytic vectors & gene-modified approaches)
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
NAICS code2 codes
  • Biological Product (except Diagnostic) Manufacturing325414
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code2 codes
  • Pharmaceutical Preparations2834
  • Biological Products, (No Disgnostic Substances)2836
Product category
Oncology Biopharmaceuticals
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Cancer immunotherapy products
TypeOne Time License
Description

Candel Therapeutics is a clinical-stage biopharmaceutical company developing viral immunotherapies for cancer. The company is pre-revenue and not yet commercializing products. It plans to commercialize aglatimagene besadenovec upon FDA approval for localized prostate cancer, with potential commercial launch in 2027. The company has secured non-dilutive royalty funding from RTW Investments contingent on FDA approval.

biospace.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Others
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Candel Therapeutics develops off-the-shelf, engineered viral immunotherapies for solid tumors, with two clinical-stage investigational products: aglatimagene besadenovec (CAN-2409), an adenoviral gene construct encoding HSV-thymidine kinase injected directly into tumors alongside oral prodrugs to trigger CD8+ T cell-mediated anti-tumor immunity, and linoserpaturev (CAN-3110), a replication-competent HSV engineered for tumor-selective killing in high-grade glioma. The company is preparing for its first commercial launch of aglatimagene in localized prostate cancer, with planned BLA submission in Q4 2026.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 8 values shown
  • 30% improvement in disease-free survival (HR 0.70, p=0.016) in localized prostate cancer Phase 3 trial
+7 more records
Product overview1 text field

Candel Therapeutics is a clinical-stage biopharmaceutical company developing two off-the-shelf viral immunotherapy platforms: the adenovirus-based platform producing aglatimagene besadenovec (CAN-2409) and the HSV-based platform producing linoserpaturev (CAN-3110). These are supported by the enLIGHTEN™ Discovery Platform for identifying new therapeutic candidates. The therapies work through localized injection to trigger systemic anti-tumor immune responses.

Product and service2 records
1Aglatimagene besadenovec (CAN-2409)
CategoryCancer immunotherapy / oncolytic gene therapy
Description

Adenoviral replication-defective gene construct encoding the HSV-thymidine kinase gene, injected directly into the tumor and combined with oral anti-herpes prodrugs (valacyclovir) to trigger immunogenic cell death and CD8+ T cell-mediated anti-tumor immunity. In development for intermediate-to-high-risk localized prostate cancer (lead indication), NSCLC, and borderline resectable pancreatic cancer.

2Linoserpaturev (CAN-3110)
CategoryOncolytic virus therapy / cancer immunotherapy
Description

Replication-competent herpes simplex virus engineered for selective killing of cancer cells; the ICP34.5 gene is placed under the Nestin promoter, enabling tumor-selective replication in Nestin-expressing high-grade glioma cells while sparing healthy adult brain cells. Supports multiple dosing without dose-limiting toxicity.

Scale indicator13 records

Each record includes

Type, Value, Description, Source

Partnership3 partners
Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2026-04-29
Description

Candel Therapeutics entered into a product commercialization agreement with EVERSANA to support the potential U.S. commercial launch of aglatimagene besadenovec for intermediate-to high-risk localized prostate cancer. Under the agreement, EVERSANA provides integrated commercialization services including data and analytics, medical affairs, market access, and field operations. The partnership gives Candel access to commercial capabilities while maintaining capital efficiency.

Strategic tierSupportingTypeStrategic or Co-development Partner
Description

Candel Therapeutics partnered with IDEA Pharma for strategic positioning as part of pre-commercial workstreams ahead of the potential launch of aglatimagene besadenovec.

3Bali Pulendran, Ph.D.
Strategic tierSupportingTypeOthers
Description

Candel Therapeutics appointed Bali Pulendran, Ph.D., an expert in systems immunology and vaccinology at Stanford University, to its Research Advisory Board. Dr. Pulendran serves as Violetta L. Horton Professor at Stanford University School of Medicine and Director of the Institute for Immunity, Transplantation and Infection.

globenewswire.com
Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Adaptimmune develops engineered T-cell receptor (TCR) therapies for solid tumors, addressing the same patient populations (sarcoma, NSCLC) and representing a comparable next-generation immuno-oncology modality to Candel's viral immunotherapy.

TypeDirect peer
Description

Vyriad develops engineered oncolytic vesicular stomatitis and measles virus platforms for solid tumor immunotherapy, with a similar in-situ vaccination mechanism to Candel's viral immunotherapies.

TypeDirect peer
Description

Genelux is a clinical-stage biopharmaceutical company developing oncolytic vaccinia virus-based therapies for cancer, directly comparable to Candel's engineered virus immunotherapy platform for solid tumors.

TypeDirect peer
Description

Replimune is a clinical-stage biotech developing oncolytic immunotherapies based on an engineered herpes simplex virus platform (RP1, RP2, RP3), making it the closest direct competitor to Candel's HSV-based CAN-3110 program and adenoviral CAN-2409 strategy.

TypeDirect peer
Description

DNAtrix develops oncolytic adenovirus and HSV therapies for brain tumors, including glioblastoma—the same indication as Candel's CAN-3110. Comparable modality and patient population.

TypeBroad incumbent
Description

Iovance is an established commercial-stage cell therapy company with FDA-approved tumor-infiltrating lymphocyte therapies for solid tumors, representing a broader oncology immunotherapy peer against which Candel's viral immunotherapy positioning competes for share of voice and capital.

7Turnstone Biologics
TypeEmerging player
Description

Turnstone Biologics is developing viral immunotherapies and tumor-infiltrating lymphocyte therapies for solid tumors, with a comparable intratumoral immunotherapy approach and overlapping solid tumor indications.

8Oncorus
TypeDirect peer
Description

Oncorus is developing intratumorally and systemically administered oncolytic virus immunotherapies for solid tumors using synthetic virotherapy platforms, comparable to Candel's intratumoral viral immunotherapy approach.

9Istari Oncology
TypeDirect peer
Description

Istari Oncology develops lerapolturev, an oncolytic HSV for recurrent glioblastoma—the same indication as Candel's CAN-3110. Its prior CMO (Garrett Nichols) is now Candel's CMO, signaling deep technical and competitive overlap.

TypeBroad incumbent
Description

Philogen develops targeted immunocytokines and antibody-based therapeutics for solid tumors including prostate cancer, representing an established intratumoral/regional immunotherapy modality competing in the same patient population as Candel.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses1 record

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles18 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance6 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds12 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors10 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Candel Therapeutics

Oncology Biopharmaceuticalscandeltx.com

Candel Therapeutics is a clinical-stage biopharmaceutical company developing off-the-shelf viral immunotherapies (adenoviral CAN-2409 and HSV-based CAN-3110) that convert solid tumors into immune-active tissue. It serves patients with prostate, lung, pancreatic, and brain cancers and is preparing a Q4 2026 BLA filing for a 2027 U.S. launch in localized prostate cancer.

What Candel Therapeutics does

Candel Therapeutics is a clinical-stage biopharmaceutical company developing off-the-shelf viral immunotherapies designed to treat solid tumors through localized intratumoral injection combined with systemic immune activation. The company's lead asset, aglatimagene besadenovec (CAN-2409), is an adenoviral replication-defective gene construct encoding the herpes simplex virus thymidine kinase gene, which is injected directly into the tumor and, in combination with FDA-approved oral prodrugs such as valacyclovir, triggers immunogenic cell death and CD8+ T cell-mediated anti-tumor immunity. Its second clinical-stage asset, linoserpaturev (CAN-3110), is a replication-competent HSV engineered for tumor-selective replication by placing the ICP34.5 gene under the Nestin promoter, enabling killing of high-grade glioma cells while sparing healthy brain tissue. Both candidates are supported by the enLIGHTEN™ Discovery Platform, an AI-assisted platform for designing new HSV-based gene constructs.

Candel's lead clinical program targets men with intermediate-to high-risk localized prostate cancer; a 745-patient Phase 3 trial under a Special Protocol Assessment met its primary endpoint with a 30% improvement in disease-free survival and an 80% pathological complete response rate, supporting a planned BLA submission in Q4 2026 and a potential U.S. commercial launch in 2027. The company has also reported positive Phase 2 data in non-small cell lung cancer (median OS 25.4 months in ICI-refractory patients), borderline resectable pancreatic cancer (median OS 31.4 months vs 12.5 months in control), and recurrent high-grade glioma, with the NSCLC program funded for Phase 3 development and the pancreatic program paused pending additional capital. Across indications the therapies have received FDA Fast Track, RMAT, and Orphan Drug designations.

The business model is presently pre-revenue. Candel is publicly listed on Nasdaq (ticker: CADL) following a 2021 IPO and operates with a lean headcount of 11-50 employees based in Needham, MA. The company has accumulated roughly $194.8M in cash and equivalents and has secured approximately $230M in additional capital during 2025-2026, including a $130M term loan facility with Trinity Capital, a $100M contingent royalty agreement with RTW Investments, and a $100M public offering, with the stated objective of funding Phase 3 development, launch readiness, and a U.S. commercial launch via an integrated commercialization partnership with EVERSANA. Future revenue, once approved, is expected to derive from product sales of aglatimagene in localized prostate cancer, subject to tiered single-digit royalties owed to RTW on U.S. net sales.

Candel Therapeutics firmographics

Firmographics
Name
Candel Therapeutics
Legal name
Candel Therapeutics
Website
https://candeltx.com
Company type
Public
Founded year
2018
Operating status
Operating
Headcount range
101–250 employees
Short description
Candel Therapeutics is a clinical-stage biopharmaceutical company developing off-the-shelf viral immunotherapies (adenoviral CAN-2409 and HSV-based CAN-3110) that convert solid tumors into immune-active tissue. It serves patients with prostate, lung, pancreatic, and brain cancers and is preparing a Q4 2026 BLA filing for a 2027 U.S. launch in localized prostate cancer.
Ownership category
akta.pro rank

Candel Therapeutics industry classification

Industry
Product category
Oncology Biopharmaceuticals
NAICS
Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAAACAF
Oncology Gene Therapies (incl. oncolytic vectors & gene-modified approaches)
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)

Keywords

  • Viral immunotherapy
  • Cancer immunotherapy
  • Oncolytic virus therapy
  • Gene therapy oncology
  • Solid tumor treatment

Where Candel Therapeutics is headquartered

Location

Headquarters

HQ city
Needham
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Candel Therapeutics business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Others

Revenue model

  1. Cancer immunotherapy products: Candel Therapeutics is a clinical-stage biopharmaceutical company developing viral immunotherapies for cancer. The company is pre-revenue and not yet commercializing products. It plans to commercialize aglatimagene besadenovec upon FDA approval for localized prostate cancer, with potential commercial launch in 2027. The company has secured non-dilutive royalty funding from RTW Investments contingent on FDA approval.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels5 records

Candel Therapeutics product offering

Product offering

Core offering

Candel Therapeutics develops off-the-shelf, engineered viral immunotherapies for solid tumors, with two clinical-stage investigational products: aglatimagene besadenovec (CAN-2409), an adenoviral gene construct encoding HSV-thymidine kinase injected directly into tumors alongside oral prodrugs to trigger CD8+ T cell-mediated anti-tumor immunity, and linoserpaturev (CAN-3110), a replication-competent HSV engineered for tumor-selective killing in high-grade glioma. The company is preparing for its first commercial launch of aglatimagene in localized prostate cancer, with planned BLA submission in Q4 2026.

Product overview

Candel Therapeutics is a clinical-stage biopharmaceutical company developing two off-the-shelf viral immunotherapy platforms: the adenovirus-based platform producing aglatimagene besadenovec (CAN-2409) and the HSV-based platform producing linoserpaturev (CAN-3110). These are supported by the enLIGHTEN™ Discovery Platform for identifying new therapeutic candidates. The therapies work through localized injection to trigger systemic anti-tumor immune responses.

Differentiator

Problem solved

Functional benefit

Products and services

  • Aglatimagene besadenovec (CAN-2409) Adenoviral replication-defective gene construct encoding the HSV-thymidine kinase gene, injected directly into the tumor and combined with oral anti-herpes prodrugs (valacyclovir) to trigger immunogenic cell death and CD8+ T cell-mediated anti-tumor immunity. In development for intermediate-to-high-risk localized prostate cancer (lead indication), NSCLC, and borderline resectable pancreatic cancer.
  • Linoserpaturev (CAN-3110) Replication-competent herpes simplex virus engineered for selective killing of cancer cells; the ICP34.5 gene is placed under the Nestin promoter, enabling tumor-selective replication in Nestin-expressing high-grade glioma cells while sparing healthy adult brain cells. Supports multiple dosing without dose-limiting toxicity.

Quantifiable outcome

  • 30% improvement in disease-free survival (HR 0.70, p=0.016) in localized prostate cancer Phase 3 trial
  • +7 more outcomes

Companies that use Candel Therapeutics

Customer profile

Segments4 records

Ideal customer profiles3 records

Candel Therapeutics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

Candel Therapeutics partnerships and signals

Strategic signal

Partnerships

Three partnerships are on record, tiered core and supporting.

  • EVERSANAcoreChannel Partner/ Reseller/ Distributor · 29 April 2026Candel Therapeutics entered into a product commercialization agreement with EVERSANA to support the potential U.S. commercial launch of aglatimagene besadenovec for intermediate-to high-risk localized prostate cancer. Under the agreement, EVERSANA provides integrated commercialization services including data and analytics, medical affairs, market access, and field operations. The partnership gives Candel access to commercial capabilities while maintaining capital efficiency.
  • IDEA PharmasupportingStrategic or Co-development PartnerCandel Therapeutics partnered with IDEA Pharma for strategic positioning as part of pre-commercial workstreams ahead of the potential launch of aglatimagene besadenovec.
  • Bali Pulendran, Ph.D.supportingOthersCandel Therapeutics appointed Bali Pulendran, Ph.D., an expert in systems immunology and vaccinology at Stanford University, to its Research Advisory Board. Dr. Pulendran serves as Violetta L. Horton Professor at Stanford University School of Medicine and Director of the Institute for Immunity, Transplantation and Infection.

Scale indicators13 records

Recent moves7 records

Expansion highlights6 records

Candel Therapeutics competitors and assessment

Company assessment

Broad incumbents

  • Adaptimmune Therapeutics: Adaptimmune develops engineered T-cell receptor (TCR) therapies for solid tumors, addressing the same patient populations (sarcoma, NSCLC) and representing a comparable next-generation immuno-oncology modality to Candel's viral immunotherapy.
  • Iovance Biotherapeutics: Iovance is an established commercial-stage cell therapy company with FDA-approved tumor-infiltrating lymphocyte therapies for solid tumors, representing a broader oncology immunotherapy peer against which Candel's viral immunotherapy positioning competes for share of voice and capital.
  • Ferring Pharmaceuticals / Philogen: Philogen develops targeted immunocytokines and antibody-based therapeutics for solid tumors including prostate cancer, representing an established intratumoral/regional immunotherapy modality competing in the same patient population as Candel.

Direct peers

  • Vyriad: Vyriad develops engineered oncolytic vesicular stomatitis and measles virus platforms for solid tumor immunotherapy, with a similar in-situ vaccination mechanism to Candel's viral immunotherapies.
  • Genelux Corporation: Genelux is a clinical-stage biopharmaceutical company developing oncolytic vaccinia virus-based therapies for cancer, directly comparable to Candel's engineered virus immunotherapy platform for solid tumors.
  • Replimune Group: Replimune is a clinical-stage biotech developing oncolytic immunotherapies based on an engineered herpes simplex virus platform (RP1, RP2, RP3), making it the closest direct competitor to Candel's HSV-based CAN-3110 program and adenoviral CAN-2409 strategy.
  • DNAtrix: DNAtrix develops oncolytic adenovirus and HSV therapies for brain tumors, including glioblastoma—the same indication as Candel's CAN-3110. Comparable modality and patient population.
  • Oncorus: Oncorus is developing intratumorally and systemically administered oncolytic virus immunotherapies for solid tumors using synthetic virotherapy platforms, comparable to Candel's intratumoral viral immunotherapy approach.
  • Istari Oncology: Istari Oncology develops lerapolturev, an oncolytic HSV for recurrent glioblastoma—the same indication as Candel's CAN-3110. Its prior CMO (Garrett Nichols) is now Candel's CMO, signaling deep technical and competitive overlap.

Emerging players

  • Turnstone Biologics: Turnstone Biologics is developing viral immunotherapies and tumor-infiltrating lymphocyte therapies for solid tumors, with a comparable intratumoral immunotherapy approach and overlapping solid tumor indications.

Market position

Strengths5 records

Weaknesses1 record

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

Candel Therapeutics social profiles

Digital presence

Candel Therapeutics compliance and trust

Trust signal

Compliance6 records

Candel Therapeutics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Candel Therapeutics leadership team

Management profile

Number of profiles

Profiles18 records

Candel Therapeutics funding detail

Funding detail

Funding overview

Funding rounds12 records

Investors10 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Candel Therapeutics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Candel Therapeutics

What does Candel Therapeutics do?

Candel Therapeutics develops off-the-shelf, engineered viral immunotherapies for solid tumors, with two clinical-stage investigational products: aglatimagene besadenovec (CAN-2409), an adenoviral gene construct encoding HSV-thymidine kinase injected directly into tumors alongside oral prodrugs to trigger CD8+ T cell-mediated anti-tumor immunity, and linoserpaturev (CAN-3110), a replication-competent HSV engineered for tumor-selective killing in high-grade glioma. The company is preparing for its first commercial launch of aglatimagene in localized prostate cancer, with planned BLA submission in Q4 2026.

Is Candel Therapeutics a public or private company?

Candel Therapeutics is a public company. It is classified as public and is currently operating.

When was Candel Therapeutics founded?

Candel Therapeutics was founded in 2018. It employs 101 to 250 people.

Where is Candel Therapeutics based?

Candel Therapeutics is headquartered in Needham, United States, in the North America region.

How does Candel Therapeutics make money?

One revenue line is on record: cancer immunotherapy products.

Who are Candel Therapeutics's main competitors?

Broad incumbents on record are Adaptimmune Therapeutics, Iovance Biotherapeutics and Ferring Pharmaceuticals / Philogen. Direct peers are Vyriad, Genelux Corporation, Replimune Group, DNAtrix, Oncorus and Istari Oncology. Turnstone Biologics is listed as an emerging player.

Does Candel Therapeutics have an API?

No public API is recorded for Candel Therapeutics.

What industry is Candel Therapeutics in?

Candel Therapeutics's product category is Oncology Biopharmaceuticals. Its primary akta.pro industry code is HLAAACAF, Oncology Gene Therapies (incl. oncolytic vectors & gene-modified approaches). Its NAICS code is 325414 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
AktienCADL INVESTORS: Securities Fraud Investigation by Block & Leviton Could Allow Candel Therapeutics Investors to Recover LossesBlock & Leviton is investigating Candel Therapeutics for potential securities law violations, focusing on whether the company misled investors about its FDA approval timeline for aglatimagene. The company had said submission was on track for Q4 2026 but later disclosed a mid-2027 submission, and shares fell about 39% after a $50 million stock sale. Investors who lost money may be eligible to recover losses.FinancialContent Business PageCADL Investor Alert: Levi & Korsinsky Notifies Investors of Investigation Into Candel Therapeutics (CADL)Candel Therapeutics delayed its aglatimagene BLA submission to mid-2027, causing a 26% stock drop. Levi & Korsinsky is investigating potential securities violations for investors who lost money. The firm offers a no-cost review of losses.PR NewswireCADL SHAREHOLDER INVESTIGATION: SueWallSt Notifies Investors of Potential Securities Claims Involving Candel TherapeuticsCandel Therapeutics delayed its aglatimagene BLA submission from Q4 2026 to mid-2027, causing its stock to fall over 26% on November 12, 2026. The company cited assay refinement and FDA dialogue as reasons. Shareholders who lost money may have securities claims.PR NewswireCandel Therapeutics Investigation Notice: Levi & Korsinsky Notifies Investors of Pending Investigation Into Candel Therapeutics (CADL)Candel Therapeutics delayed its aglatimagene BLA submission to mid-2027, causing a 26% stock drop. The company had raised $80 million for the submission, and Levi & Korsinsky is investigating potential securities law violations. Investors who suffered losses may be eligible for compensation.GlobeNewswireCandel Therapeutics (CADL) Faces Investor Scrutiny After Surprise BLA Delay Drives Stock 26% Lower – HBSSCandel Therapeutics delayed its BLA submission for aglatimagene, causing its stock to fall 26% on November 13, 2026. Hagens Berman opened an investigation into whether prior 'on track' assurances misled investors. The firm seeks trading information from investors with substantial losses.TradingViewCitigroup maintains Candel Therapeutics at Buy, lowers price target to $20 from $26Citigroup maintained Candel Therapeutics at Buy and lowered its price target to $20 from $26, a 23.1% decrease. The target implies an upside of 222.6% from the Nov 13 close of $6.20. Recent analyst price targets range from $13 to $25.The future of tradingCADL SHAREHOLDER INVESTIGATION: Levi & Korsinsky Notifies Investors of Potential Securities Claims Involving Candel Therapeutics, IncLevi & Korsinsky notified investors of an investigation into Candel Therapeutics over potential securities law violations. Candel's shares fell 26% after it delayed its BLA submission to mid-2027 and reported a $21.9 million quarterly net loss. The firm is seeking to review shareholder rights for those who suffered losses.The Pharma LetterCandel delays prostate cancer filing to mid-2027Candel Therapeutics delayed its planned application to the FDA for prostate cancer immunotherapy aglatimagene besadenovec to mid-2027, from this year. The delay was attributed to assay refinement timelines, with the submission date dependent on ongoing FDA discussions.FinancialContent Business PageCADL Investor Alert: Levi & Korsinsky Notifies Investors of Investigation Into Candel Therapeutics, Inc. (CADL)Levi & Korsinsky is investigating Candel Therapeutics for potential securities fraud after the company delayed its aglatimagene BLA submission to mid-2027, causing a 39% after-hours drop. The firm is seeking investors who suffered losses from the disclosure.TradingViewHC Wainwright & Co. maintains Candel Therapeutics at Buy, lowers price target to $18 from $23HC Wainwright & Co. maintained Candel Therapeutics at Buy and lowered its price target to $18 from $23, a 21.7% decrease. The target implies an upside of 114.5% from the Nov 12 close of $8.39. Recent analyst price targets range from $13 to $25.